Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Orexin signaling during social defeat stress influences subsequent social interaction behaviour and recognition memory.

Eacret D, Grafe LA, Dobkin J, Gotter AL, Renger JJ, Winrow CJ, Bhatnagar S.

Behav Brain Res. 2019 Jan 1;356:444-452. doi: 10.1016/j.bbr.2018.05.032. Epub 2018 Jun 11.

PMID:
29902478
2.

The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.

Yao L, Ramirez AD, Roecker AJ, Fox SV, Uslaner JM, Smith SM, Hodgson R, Coleman PJ, Renger JJ, Winrow CJ, Gotter AL.

J Neurochem. 2017 Jul;142(2):204-214. doi: 10.1111/jnc.14055. Epub 2017 Jun 1.

3.

Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress.

Grafe LA, Eacret D, Luz S, Gotter AL, Renger JJ, Winrow CJ, Bhatnagar S.

Neuroscience. 2017 Apr 21;348:313-323. doi: 10.1016/j.neuroscience.2017.02.038. Epub 2017 Feb 28.

4.

Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.

Skudlarek JW, DiMarco CN, Babaoglu K, Roecker AJ, Bruno JG, Pausch MA, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Wuelfing WP, Garson SL, Fox SV, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Kuduk SD, Coleman PJ.

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1364-1370. doi: 10.1016/j.bmcl.2017.02.012. Epub 2017 Feb 9.

PMID:
28216403
5.

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.

Coleman PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:509-533. doi: 10.1146/annurev-pharmtox-010716-104837. Review.

PMID:
27860547
6.

Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.

Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, McDonald TP, O'Brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5809-5814. doi: 10.1016/j.bmcl.2016.10.019. Epub 2016 Oct 14.

PMID:
27818110
7.

Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain.

McDonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ.

J Neurogenet. 2016 Mar;30(1):32-41. doi: 10.3109/01677063.2016.1171862.

PMID:
27276194
8.

Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.

Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ.

Sci Rep. 2016 Jun 3;6:27147. doi: 10.1038/srep27147.

9.

Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuermann TH, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman PJ, Rosenbaum DM.

Nat Struct Mol Biol. 2016 Apr;23(4):293-9. doi: 10.1038/nsmb.3183. Epub 2016 Mar 7.

PMID:
26950369
10.

Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.

Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ.

Sleep. 2016 Mar 1;39(3):603-12. doi: 10.5665/sleep.5536.

11.

Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.

Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2015 Jun 15;25(12):2488-92. doi: 10.1016/j.bmcl.2015.04.066. Epub 2015 Apr 29.

PMID:
25981685
12.

Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.

Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4992-4999. doi: 10.1016/j.bmcl.2014.12.081. Epub 2015 Jan 6.

PMID:
25613676
13.

Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.

Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):444-50. doi: 10.1016/j.bmcl.2014.12.056. Epub 2014 Dec 23.

PMID:
25577040
14.

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90. doi: 10.1016/j.bmcl.2014.08.041. Epub 2014 Aug 26.

PMID:
25248679
15.

Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.

Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ.

BMC Neurosci. 2014 Sep 22;15:109. doi: 10.1186/1471-2202-15-109.

16.

Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs.

Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ.

Front Behav Neurosci. 2014 May 16;8:182. doi: 10.3389/fnbeh.2014.00182. eCollection 2014.

17.

Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement.

Uslaner JM, Winrow CJ, Gotter AL, Roecker AJ, Coleman PJ, Hutson PH, Le AD, Renger JJ.

Behav Brain Res. 2014 Aug 1;269:61-5. doi: 10.1016/j.bbr.2014.04.012. Epub 2014 Apr 18.

PMID:
24746488
18.

Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.

Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2014 May 1;24(9):2079-85. doi: 10.1016/j.bmcl.2014.03.052. Epub 2014 Mar 26.

PMID:
24704030
19.

Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.

Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1784-9. doi: 10.1016/j.bmcl.2014.02.026. Epub 2014 Feb 19.

PMID:
24630562
20.

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.

Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ.

Front Neurosci. 2013 Dec 24;7:254. doi: 10.3389/fnins.2013.00254. eCollection 2013.

21.

Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ.

ChemMedChem. 2014 Feb;9(2):311-22. doi: 10.1002/cmdc.201300447. Epub 2013 Dec 27.

PMID:
24376006
22.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.

Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ.

BMC Neurosci. 2013 Aug 28;14:90. doi: 10.1186/1471-2202-14-90.

23.

Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.

Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ.

Neuropsychopharmacology. 2013 Nov;38(12):2401-8. doi: 10.1038/npp.2013.139. Epub 2013 May 31.

24.

Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition.

Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ.

Sci Transl Med. 2013 Apr 3;5(179):179ra44. doi: 10.1126/scitranslmed.3005213.

25.

Orexin receptors as therapeutic drug targets.

Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ.

Prog Brain Res. 2012;198:163-88. doi: 10.1016/B978-0-444-59489-1.00010-0. Review.

PMID:
22813974
26.

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.

Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ.

Pharmacol Rev. 2012 Jul;64(3):389-420. doi: 10.1124/pr.111.005546. Review.

PMID:
22759794
27.

Altered sleep and affect in the neurotensin receptor 1 knockout mouse.

Fitzpatrick K, Winrow CJ, Gotter AL, Millstein J, Arbuzova J, Brunner J, Kasarskis A, Vitaterna MH, Renger JJ, Turek FW.

Sleep. 2012 Jul 1;35(7):949-56. doi: 10.5665/sleep.1958.

28.

Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.

Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ.

ChemMedChem. 2012 Mar 5;7(3):415-24, 337. doi: 10.1002/cmdc.201200025. Epub 2012 Feb 3.

PMID:
22307992
29.

Pharmacological validation of candidate causal sleep genes identified in an N2 cross.

Brunner JI, Gotter AL, Millstein J, Garson S, Binns J, Fox SV, Savitz AT, Yang HS, Fitzpatrick K, Zhou L, Owens JR, Webber AL, Vitaterna MH, Kasarskis A, Uebele VN, Turek F, Renger JJ, Winrow CJ.

J Neurogenet. 2011 Dec;25(4):167-81. doi: 10.3109/01677063.2011.628426.

30.

Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.

Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ.

Neuropharmacology. 2012 Feb;62(2):978-87. doi: 10.1016/j.neuropharm.2011.10.003. Epub 2011 Oct 18.

PMID:
22019562
31.

Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).

Coburn CA, Luo Y, Cui M, Wang J, Soll R, Dong J, Hu B, Lyon MA, Santarelli VP, Kraus RL, Gregan Y, Wang Y, Fox SV, Binns J, Doran SM, Reiss DR, Tannenbaum PL, Gotter AL, Meinke PT, Renger JJ.

ChemMedChem. 2012 Jan 2;7(1):123-33. doi: 10.1002/cmdc.201100351. Epub 2011 Sep 14.

PMID:
21916012
32.

TASK-3 as a potential antidepressant target.

Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, Meziane H, Montial M, Reiss DR, Wessner K, McCampbell A, Stevens J, Brunner JI, Fox SV, Uebele VN, Bayliss DA, Winrow CJ, Renger JJ.

Brain Res. 2011 Oct 6;1416:69-79. doi: 10.1016/j.brainres.2011.08.021. Epub 2011 Aug 16.

33.

Timeless links replication termination to mitotic kinase activation.

Dheekollu J, Wiedmer A, Hayden J, Speicher D, Gotter AL, Yen T, Lieberman PM.

PLoS One. 2011 May 6;6(5):e19596. doi: 10.1371/journal.pone.0019596.

34.

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.

Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ.

J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8. Erratum in: J Neurogenet. 2016 Sep - Dec;30(3-4):316.

PMID:
21473737
35.

In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.

Kraus RL, Li Y, Gregan Y, Gotter AL, Uebele VN, Fox SV, Doran SM, Barrow JC, Yang ZQ, Reger TS, Koblan KS, Renger JJ.

J Pharmacol Exp Ther. 2010 Nov;335(2):409-17. doi: 10.1124/jpet.110.171058. Epub 2010 Aug 3.

PMID:
20682849
36.

Tricyclic imidazole antagonists of the Neuropeptide S Receptor.

Trotter BW, Nanda KK, Manley PJ, Uebele VN, Condra CL, Gotter AL, Menzel K, Henault M, Stocco R, Renger JJ, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4704-8. doi: 10.1016/j.bmcl.2010.04.016. Epub 2010 Apr 13.

PMID:
20615693
37.

Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists.

Melamed JY, Zartman AE, Kett NR, Gotter AL, Uebele VN, Reiss DR, Condra CL, Fandozzi C, Lubbers LS, Rowe BA, McGaughey GB, Henault M, Stocco R, Renger JJ, Hartman GD, Bilodeau MT, Trotter BW.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4700-3. doi: 10.1016/j.bmcl.2010.04.143. Epub 2010 May 5.

PMID:
20510609
38.

Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.

Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, Uebele VN, Doran SM, Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ.

Neuropharmacology. 2010 Jan;58(1):185-94. doi: 10.1016/j.neuropharm.2009.07.008. Epub 2009 Jul 14.

PMID:
19596018
39.

Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.

Uebele VN, Gotter AL, Nuss CE, Kraus RL, Doran SM, Garson SL, Reiss DR, Li Y, Barrow JC, Reger TS, Yang ZQ, Ballard JE, Tang C, Metzger JM, Wang SP, Koblan KS, Renger JJ.

J Clin Invest. 2009 Jun;119(6):1659-67. doi: 10.1172/JCI36954. Epub 2009 May 18.

40.

A palindrome-driven complex rearrangement of 22q11.2 and 8q24.1 elucidated using novel technologies.

Gotter AL, Nimmakayalu MA, Jalali GR, Hacker AM, Vorstman J, Conforto Duffy D, Medne L, Emanuel BS.

Genome Res. 2007 Apr;17(4):470-81. Epub 2007 Mar 9.

41.

Mammalian TIMELESS and Tipin are evolutionarily conserved replication fork-associated factors.

Gotter AL, Suppa C, Emanuel BS.

J Mol Biol. 2007 Feb 9;366(1):36-52. Epub 2006 Nov 3.

42.

A Timeless debate: resolving TIM's noncircadian roles with possible clock function.

Gotter AL.

Neuroreport. 2006 Aug 21;17(12):1229-33. Review.

PMID:
16951560
43.

A palindrome-mediated mechanism distinguishes translocations involving LCR-B of chromosome 22q11.2.

Gotter AL, Shaikh TH, Budarf ML, Rhodes CH, Emanuel BS.

Hum Mol Genet. 2004 Jan 1;13(1):103-15. Epub 2003 Nov 12.

44.

A novel sequence-based approach to localize translocation breakpoints identifies the molecular basis of a t(4;22).

Nimmakayalu MA, Gotter AL, Shaikh TH, Emanuel BS.

Hum Mol Genet. 2003 Nov 1;12(21):2817-25. Epub 2003 Sep 2.

PMID:
12952865
46.

Constructing a feedback loop with circadian clock molecules from the silkmoth, Antheraea pernyi.

Chang DC, McWatters HG, Williams JA, Gotter AL, Levine JD, Reppert SM.

J Biol Chem. 2003 Oct 3;278(40):38149-58. Epub 2003 Jul 17.

47.

Illuminating the circadian clock in monarch butterfly migration.

Froy O, Gotter AL, Casselman AL, Reppert SM.

Science. 2003 May 23;300(5623):1303-5.

48.

Analysis of human Per4.

Gotter AL, Reppert SM.

Brain Res Mol Brain Res. 2001 Aug 15;92(1-2):19-26.

PMID:
11483238
49.

Electrophorus electricus as a model system for the study of membrane excitability.

Gotter AL, Kaetzel MA, Dedman JR.

Comp Biochem Physiol A Mol Integr Physiol. 1998 Jan;119(1):225-41. Review.

PMID:
11253789
50.

A time-less function for mouse timeless.

Gotter AL, Manganaro T, Weaver DR, Kolakowski LF Jr, Possidente B, Sriram S, MacLaughlin DT, Reppert SM.

Nat Neurosci. 2000 Aug;3(8):755-6.

PMID:
10903565

Supplemental Content

Loading ...
Support Center